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ABSTRACT
Objectives To confirm the hypothesis that isolated cardiac
echogenic foci at the second-trimester anomaly scan do not
influence our current calculation of risk of trisomy 21 in
individual pregnancies, which is based on maternal age and
nuchal translucency thickness at 11–14 weeks.
Design Observational study in a fetal medicine unit.
Methods In a general pregnant population undergoing
first-trimester nuchal translucency screening, data from 239
singleton pregnancies with isolated cardiac echogenic foci at
the second-trimester anomaly scan were compared with those
of a control group of 7449 pregnancies with normal anomaly
scans. Prevalence of trisomy 21 was determined in both groups.
Following the anomaly scan, the individual risks of trisomy
21 were calculated by adjusting the previous risk based on
maternal age and first-trimester nuchal translucency. We
assumed that echogenic foci did not alter each individual
risk calculation. The expected number of cases of Down
syndrome in both groups was then calculated from the sum
of probabilities of each individual affected fetus. The observed
number of cases was compared with the expected number in
both study and control populations.
Results There was no statistically significant difference between
the prevalence of trisomy 21 in the study group (no cases) and
in the control population (three cases). From individual
risk calculations, observing no cases of trisomy 21 in the
study group was the most likely event if echogenic foci did
not increase the risk of this chromosomal abnormality
(P = 0.62).
Conclusion The finding of isolated echogenic foci at the time
of the 20 week-scan does not significantly change the risks of
trisomy 21 if background risk and previous nuchal translucency
measurements are taken into account in the individual risk
calculation. We suggest that no further adjustments to risk
should be used.
INTRODUCTION
Cardiac echogenic foci are small structures visualized within
the fetal heart, of echogenicity similar to or greater than that
of the surrounding bone. They were first reported in 1987 as a
benign sonographic finding1. Since then their reported prev-
alence among different series has varied from 0.5%2 to 20%3
depending on the characteristics of the various populations
studied. As a cardiac structure, they pose no hemodynamic dis-
turbance, and when observed in an apparently normal four-
chamber view they do not seem to be associated with structural
cardiac abnormalities4. However, much debate exists regarding
their significance as a marker for chromosomal abnormality,
especially as a marker for trisomy 21.
In clinical practice, based on available information in the
literature, ascertainment of risks of fetal aneuploidy for
individual pregnancies following the detection of an isolated
echogenic focus in the fetal heart is controversial. Several
studies have indicated that if found in isolation, echogenic foci
are not associated with an increased risk of aneuploidy5–8,
while others report a significantly increased risk9–11. A recent
review supports the idea that this sonographic finding may
increase the risk of chromosomal abnormality if found in
high-risk groups, but not otherwise12.
The purpose of this study was to test the hypothesis that
isolated cardiac echogenic foci are not significant markers for
trisomy 21 in a population previously screened by nuchal
translucency (NT) in the first trimester of pregnancy. If this
hypothesis is correct, the recognition of echogenic foci during
a routine anomaly scan should not affect our current method
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of risk assessment for this chromosomal abnormality, which is
based on maternal age, first-trimester NT measurements and
ultrasound findings at the 20-week scan.
MATERIALS AND METHODS
Study group
All fetuses in pregnancies booked into and delivered at our
hospital and identified from our computerized clinical database
as having had both a nuchal translucency scan and a sub-
sequent anomaly scan showing isolated cardiac echogenic
foci between January 1997 and June 2000 were included in
our study group. Pregnancies referred from other hospitals
were excluded from the study.
All fetuses had routine first-trimester nuchal translucency
scans and second-trimester anomaly scans performed by
experienced sonographers or obstetricians, using standard
obstetric mode ultrasound machine settings. During the study
period, most fetuses also had detailed fetal echocardiography
as part of our risk assessment for chromosomal abnormalities
in individual pregnancies. The anatomy of the fetal heart was
assessed using a sequential segmental approach13, comple-
mented by the use of color flow mapping and pulsed wave
Doppler as indicated. All scans were carried out with either
a 3.5- or a 5-MHz curvilinear probe, using various ultrasound
machines (ATL, Letchworth, UK; Acuson, Uxbridge, UK;
General Electrics, UK; Diasonics, UK).
Fetuses which were found to have any other recognized marker
for chromosomal abnormality or a definite abnormality at the
time of the 20-week scan were excluded from further analysis.
Also excluded were cases of multiple gestation. Those fetuses
which had been shown to have increased nuchal translucency
measurements at the time of the first-trimester scan (10–14
weeks), but an otherwise normal anomaly scan were not excluded
from analysis as nuchal translucency measurements were taken
into account in the calculation of risk of chromosomal abnor-
malities for individual patients at the time of the 20-week scan.
Control group
All fetuses from pregnancies booked and delivered at our hos-
pital who had both first- and second-trimester scans at our
center during the study period, and in whom neither fetal
abnormalities nor markers for chromosomal abnormalities
had been detected at the time of the 20-week scan, were
included in the control group. All referrals were excluded.
Follow up
Hospital records were reviewed to determine delivery outcomes
for each subject. Results were also cross-matched with the reg-
istry of the Regional Genetics Service, covering genetic and
cytogenetic testing for the whole area referring to our hospital.
Statistical analysis and calculation of risk of trisomy 21
The prevalence of trisomy 21 was determined in both the
control and the study groups. Confidence intervals for this
prevalence were calculated using the exact binomial method14.
The prevalences in the two groups were compared using
Fisher’s exact test15.
In order to test the hypothesis that the presence of isolated
echogenic foci does not alter the risk of trisomy 21, we used a
commercially available database (PIA-Fetal Database version
3.21, ViewPoint Bildverarbeitung GmbH, Germany) which
is routinely used in our department for the calculations of risk
of chromosomal abnormalities. For the risk of trisomy 21,
the background risk related to maternal age is adjusted
according to other known variables for the particular preg-
nancy being assessed. History of previously affected pregnancies,
first-trimester measurement of nuchal translucency thickness
and ultrasound findings at the time of the anomaly scan
(abnormalities as well as soft markers) are taken into account
in order to provide an estimate of the risk for the individual
pregnancy. Adjustments made to the background risk (maternal
age related) due to nuchal translucency thickness are based on
the distribution of this measurement in the general population16,
while adjustments related to fetal anomalies or markers are
based on a review of the available literature17. In the absence
of fetal abnormalities or markers for chromosomal abnorm-
alities, a likelihood ratio of 0.6 is used to adjust the risks at
the time of the anomaly scan.
For the purpose of this study, in the calculation of risk of
trisomy 21, the echogenic focus was considered as a non-
marker in the study group i.e. with the assumption that the
anomaly scan showed no soft markers. Therefore, for every
patient in both the control and the study groups, individual
risk was calculated taking into account maternal age, nuchal
measurements and absence of abnormalities or soft markers.
In this way, each individual risk is decreased further at 20 weeks.
Thus, with this approach, and for each pregnancy, the lowest
(and best) possible estimated risk of that particular fetus having
trisomy 21 was obtained.
In both groups, the sum of risks of each fetus having trisomy
21 was obtained in order to ascertain the expected number
of cases of this chromosomal abnormality in each group based
on individual probabilities. This expected number of cases
was then used to calculate the probability of observing cases
of Down syndrome using the exact binomial distribution14.
The number of abnormalities observed should follow a Poisson
distribution with mean equal to the expected number. The
probabilities of encountering cases of Down syndrome for
such a distribution were calculated using the Poisson prob-
ability formula:
exp(− m)mr/r!, 
where r is the number of abnormalities and m the expected
number of abnormalities, the mean of the Poisson distribution14.
The same probability was calculated in the control group, in
order to verify the appropriateness of the method.
RESULTS
The prevalence of isolated cardiac echogenic foci in the
population studied was 3.1% (239/7688; 95% confidence
interval, 2.7–3.5%). There were no cases of trisomy 21 in this
group of fetuses. During the same time period (Figure 1), 15
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cases of trisomy 21 were identified and confirmed antenatally
by a combination of maternal age and nuchal translucency
thickness in the first trimester of pregnancy. After chorionic
villus sampling, all pregnancies were either terminated or
miscarried spontaneously and it was not possible to perform
a complete anomaly scan; therefore, these cases were excluded
from our analysis. In two other cases, the risk of trisomy 21
was 1 : 27 and 1 : 203 but the families declined invasive tests.
An atrioventricular septal defect was diagnosed at 20 weeks
in one case and no abnormalities or markers were detected in
the other. In both, trisomy 21 was confirmed postnatally.
Another two cases were considered low risk for aneuploidy
following nuchal translucency screening. Both had multiple
markers on the anomaly scan, one with and one without
echogenic foci. Two other cases diagnosed postnatally were
considered low risk for trisomy 21 at 11–14 weeks and showed
no obvious abnormalities or markers at the 20 week-scan.
Another two cases of Down syndrome were identified at
20 weeks in pregnancies where nuchal translucency was not
assessed. These were identified by multiple markers or fetal
abnormalities, one with and one without echogenic foci.
Study group
A total of 239 fetuses having had a nuchal translucency scan
and showing isolated intracardiac echogenic foci at the anomaly
scan were identified. Mean maternal age was 30.0 years
(standard deviation, 5.4 years; range, 15–42 years; median,
30 years). Of these, 20.5% (n = 49) of the mothers were
35 years or older. For three of the fetuses, the position of the
echogenic focus was not recorded. Among the remaining 236
fetuses, 82% had an echogenic focus in the left ventricle
(n = 194), 6% in the right ventricle (n = 13), and 12% had
bilateral foci (n = 29). There were no cases of chromosomal
abnormalities in the study group.
Control group
A total of 7449 fetuses had a nuchal translucency scan and a
normal anomaly scan. Mean maternal age was 30.2 years
(standard deviation, 5.4 years; range, 14–51 years; median,
31 years). Of these, 21.8% (n = 1627) of the mothers were
35 years or older.
Differences in mean maternal age and in the percentage of
women of 35 years or older between the study group and the
control group were not significant (P = 0.44, Student’s t-test
and P = 0.62, χ2 test, respectively). There were three babies
with trisomy 21 in this group, all diagnosed postnatally.
Statistical analysis
The prevalence of trisomy 21 in the study group was 0 per
1000, with a 95% confidence interval of 0–15 per 1000. The
prevalence of trisomy 21 in the control group was 0.39 per
1000, with a 95% confidence interval of 0.08–1.1 per 1000.
The prevalence in the two groups did not show a statistic-
ally significant difference: there were no cases of trisomy 21
among 239 subjects in the study group and three cases
among 7449 subjects in the control group (P = 0.91, Fisher’s
exact test).
Analysis of the assessment of risk of trisomy 21
Study group The expected number of cases of trisomy 21 in
the study group (sum of all individual probabilities) was 0.48.
Applying the exact binomial distribution, the probability of
finding no abnormalities in the study group was 0.62, the
probability of finding one case of trisomy 21 was 0.30, and
the probability of encountering two or more abnormalities
was 0.08. Hence, our finding of no cases of Down syndrome
in the study group did not differ significantly from the expected
distribution in the population we studied and was the most
likely probability (n = 0, P = 0.62).
Control group Utilizing a similar analysis, the expected number
of cases of trisomy 21 in the control group was 5.6. The prob-
ability of finding three abnormalities was 0.11, the probability
of observing between four and six abnormalities was 0.48
and that of seven or more was 0.33. Consequently, the observed
number of anomalies (three cases) was not significantly
different from the expected distribution (P = 0.11). This was,
however, the less likely probability.
Nuchal translucency
 screening 
3 T21
postnatal diagnoses
No cases
of T21 
2 T21 fetuses,
multiple markers/
abnormalities
No nuchal translucency
screening
15 T21 (TOP or IUD)
(no anomaly scan)
7449 normal
anomaly scans
‘no foci’
239 normal
anomaly scans
‘+ isolated  foci’
3 T21 fetuses,
multiple  markers/
abnormalities
Figure 1 Summary of prenatal ultrasound findings in all cases of trisomy 21 diagnosed during the study period. T21, trisomy 21; TOP, termination 
of pregnancy; IUD, intrauterine death.
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DISCUSSION
This study confirmed the hypothesis that when isolated
echogenic foci are not considered ‘soft markers’ for trisomy
21 in a population previously screened by nuchal translucency,
the risks of this chromosomal abnormality have not been
underestimated. We showed no statistical difference between
the prevalence of trisomy 21 in the study and control groups.
Furthermore, we demonstrated that the frequency of observed
cases of Down syndrome in the study group (no cases) fell
within the calculated probability of observing no cases in the
population we studied and that this was the most likely event
to occur (P = 0.62). The implications are that such an assump-
tion can be made when calculating the risks of a particular
fetus having this specific chromosomal abnormality.
The prevalence of echogenic foci in prospective studies in the
general low-risk population is variable5–8. Its rate of detec-
tion seems, however, to be increasing. The reason for this is
likely to be multifactorial, including, for example, the use of
modern ultrasound equipment, the wider use of multiple views
to assess the fetal heart and the move towards earlier scans.
It is generally accepted that echogenic foci ‘disappear’ towards
late gestation and early infancy2,5,6 and that their prevalence
is higher in the first trimester7. In our experience, the absolute
size of the foci does not seem to change significantly during
pregnancy, but their relative size is considerably less later in gesta-
tion. We therefore feel that as their size remains relatively
stable, they are progressively and relatively smaller as the fetus
and the surrounding cardiac structures grow, until they are
no longer easily visible.
The majority of fetuses with this finding are karyotypically
normal. However, data from pathological studies have suggested
an association with trisomies 13 and 2118. Such an association
has been confirmed in studies of high-risk pregnancies19–23
but not in studies of low-risk populations5–8; one of which5
specifically addressed fetuses with cardiac echogenic foci
with no associated anomalies. Risks of chromosomal abnorm-
ality associated with an isolated echogenic focus have been
calculated. Simpson and colleagues9 analyzed a series of 228
fetuses with this isolated finding from a low-risk maternal
population (aged < 35 years) and found two cases of chro-
mosomal abnormalities diagnosed postnatally: one case each
of trisomy 21 and unbalanced translocation. The authors
concluded that isolated cardiac echogenic foci are associated
with an overall prevalence of 1% of chromosomal abnormality
and suggested that fetal karyotype should be considered
in every case found to have an isolated focus. Nyberg and
colleagues24 adjusted maternal age-related risk according to
sonographic findings by assigning a likelihood ratio of 2 for
echogenic foci and 0.4 for a normal ultrasound. Thilaganathan
and colleagues8 did not find any significant association
between isolated cardiac echogenic foci and Down syndrome
in a general population which had been screened by either
nuchal translucency or maternal serum biochemistry. Thus
far, however, measurements of first-trimester nuchal trans-
lucency have not been systematically taken into account in
conjunction with ultrasound findings and maternal age in
the analysis of risk of trisomy 21 in fetuses presenting with
isolated echogenic foci in the heart.
The group of patients we studied originated from a hospital-
based population which represents a general population and
constitutes a mixture of low- and high-risk pregnancies. The
population was of approximately 50% Caucasian ethnic origin
and 50% Afro-Caribbean so no overestimation of the prevalence
of echogenic foci due to their higher frequency in Asian popu-
lations should have occurred25. The fetuses which formed the
study group were selected from this general population by a
single criterion: the finding of cardiac echogenic foci and
no other markers or abnormalities on the ultrasound scan.
All anomaly scans were carried out in our fetal medicine
department, which is a tertiary center. This is an important
consideration as we feel confident that all cases included
in our study group had had a thorough examination to
exclude fetal abnormalities as well as other ‘soft markers’.
It is of major importance to consider that, among the 21
cases of Down syndrome observed during the study period
which had first-trimester risk assessment based on maternal age
and NT, 15 affected pregnancies were diagnosed in early gesta-
tion following fetal karyotyping. None of these pregnancies
were ongoing and therefore the prevalence of trisomy 21 at
the time of the anomaly scan was decreased. Consequently,
the specificity and positive predictive value of any ultrasound
marker for Down syndrome was lower compared to a popula-
tion not undergoing an effective program of screening. This may
account for the lower observed number of cases of trisomy 21
in the control group (n = 3) compared to the calculated expected
number (n = 5.6).
In previous studies addressing the significance of cardiac
echogenic foci, the populations studied were often not homo-
geneous in respect to the type of Down syndrome screening
received, if any at all. Since screening programs affect the
prevalence of trisomy 21 later in gestation, it is not straight-
forward to extrapolate the significance of ultrasound markers
from selected populations or from populations whose char-
acteristics have not been properly described. We feel it is
inappropriate to generalize the risks of chromosomal abnorm-
ality and to act upon this generalization as there are risks
of fetal loss associated with invasive karyotyping procedure.
We suggest that assessing individual risks taking into account
all data available for the specific pregnancy, as demonstrated
in this study, offers a more logical approach for individual
patients.
We were only able to calculate the risk for trisomy 21, not
the risk for all possible chromosomal abnormalities. Since
NT screening has been proved to be effective for screening
trisomies 18 and 13 and sex chromosomal abnormalities26–28,
we think that the considerations expressed above should also
apply to these aneuploidies. However, larger populations are
required to confirm this.
All our patients had detailed scans by experienced personnel.
This must also be taken into account before the examination
is considered not to have shown any soft markers or definite
abnormalities as these findings could change individual
risks considerably. We are in agreement with Sepulveda and
Romero12 that as the echogenic focus is usually easily seen
during routine anomaly scan, this should prompt a detailed
fetal examination. If this examination, to include a detailed
assessment of the four-chamber view, is to be performed
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locally at district hospitals or at tertiary referral centers, there
should be a policy for each individual unit to reach a decision
based on the level of expertise available locally. Whether
cardiac assessment should also include the great vessels is
a matter of debate, as thus far there have been little data to
suggest that the presence of an echogenic focus in an otherwise
normal four-chamber view is associated with higher pre-
valence of congenital heart disease than that expected in
the general population4. In addition, if about 3% of the popula-
tion presents an echogenic focus, there might not, as yet, be
enough resources to provide detailed fetal echocardiography
for every case shown to have a normal four-chamber view with
an echogenic focus.
Based on all of the above, and facing a patient in whom
there are no other findings on the anomaly scan, our current
risk assessment for trisomy 21 consists of taking into account
only maternal age and NT. Until larger studies can confirm
our analysis, we suggest that in clinical practice no further
adjustment is made to the risk (assuming a likelihood ratio of 1),
i.e. the risk should be neither decreased because the anomaly
scan is normal, nor increased.
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